Culturally Adapted i-CBT for Farsi/Dari Speaking Migrants
Launched by KAROLINSKA INSTITUTET · Feb 13, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new online therapy program designed for young migrants and refugees who speak Farsi or Dari. The goal is to see if this culturally adapted internet-based cognitive behavioral therapy (i-CBT) can help reduce common mental health issues like depression, anxiety, and stress. Researchers believe that the program will significantly improve participants' mental well-being compared to those who do not receive the therapy.
To participate, individuals need to be between 15 and 29 years old, have a refugee or migrant background, and score above a certain level on a mental health questionnaire. They must also have reliable internet access and be comfortable using a computer or smartphone. It's important to note that those with severe mental health conditions, substance abuse issues, or who are currently receiving psychological treatment will not be eligible for this trial. Participants can expect to commit to the program for 6 to 10 weeks, engaging in activities designed to improve their mental health in a supportive, culturally relevant way.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between the ages of 15 and 29.
- • A score above the cut-off 1.75 on HSCL-25
- • Has a refugee or migrant background
- • Has a good and stable internet connection
- • Has access to a computer, tablet or smartphone
- • Is fluent in reading and writing Arabic
- • Has the ability to dedicate time to take part in the intervention for 6-10 weeks.
- Exclusion Criteria:
- • Is suffering from a severe mental illness, such as psychosis or severe depression.
- • Is suffering from substance abuse
- • Is undergoing a psychological treatment
- • Has a high risk of suicide
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Gerhard Andersson, PhD
Principal Investigator
Linkoeping University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported